Guardant Health, Inc.

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
91.20 ^USD	-1.49%		-2.88%	-10.71%

03-05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
03-04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI

Morgan Stanley Adjusts Guardant Health's Price Target to $55 From $60, Keeps Overweight Rating

Published on 08/07/2023 at 04:44 pm BST - Modified on 08/07/2023 at 04:45 pm BST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Guardant Health, Inc.

03-05	Guardant Health Insider Sold Shares Worth $3,812,661, According to a Recent SEC Filing	MT
03-04	Guardant Health Launches Coast-To-Coast Screening Tour, Bringing Shield Colon Cancer Blood Test to over 100 Communities Across America	CI
02-19	Guardant Health, Inc., Q4 2025 Earnings Call, Feb 19, 2026
02-19	(GH) Guardant Health Expects Full Year 2026 Revenue Range $1.25B - $1.28B, vs. FactSet Est of $1.25B	MT
02-19	Guardant Health Q4 Adjusted Loss Narrows, Revenue Rises; 2026 Revenue Guidance Set	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Reports Q4 Revenue $281.3M, vs. FactSet Est of $272.4M	MT
02-19	Earnings Flash (GH) Guardant Health, Inc. Posts Q4 Adjusted Loss $0.50 per Share, vs. FactSet Est of $-0.77	MT
02-19	Guardant Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-19	Guardant Health, Inc. Provides Revenue Guidance for the Fiscal Year 2026	CI
02-18	Guardant Health, Inc. (NasdaqGS:GH) acquired Metasight Diagnostics for approximately $150 million.	CI
02-17	Baird Initiates Guardant Health at Outperform With $120 Price Target	MT
02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT
01-22	Guardant Health, Inc. Receives FDA Approval for Guardant360®? CDx as Companion Diagnostic for BRAFTOVI®? (Encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	CI
01-22	Guardant Health Receives FDA Approval for Colorectal Cancer Diagnostic	MT

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Employees

2,498

Sector

Medical Equipment, Supplies & Distribution

More about the company